Sanitas AB - Notification on material event

NOTIFICATION OF THE PROPOSED TRANSACTION TO A COMPETITION AUTHORITY

Kaunas, Lithuania, 2011-06-10 08:40 CEST (GLOBE NEWSWIRE) -- AB Sanitas
announces that Valeant Pharmaceuticals International, Inc. (“Valeant”)
yesterday, 9th June 2011, submitted an application to the Antimonopoly
Committee of Ukraine for clearance of the proposed transaction. This
application has also been made in connection with Valeant's intended
acquisition of the 87.2% shareholding in AB Sanitas from the funds advised by
Citi Venture Capital International (“CVCI”, through the legal entities
Citigroup Venture Capital International Jersey Limited and Baltic Pharma
Limited), AB Invalda (“Invalda”), Amber Trust II S.C.A. (“Amber”) and certain
other persons (together the “Controlling Shareholders”). More information is
available at:
http://www.sanitasgroup.com/index.php/news/news/the-signature-date-of-the-share-
sale-and-purchase-agreement-has-been-corrected/11468;
http://www.sanitasgroup.com/index.php/news/news/notification-of-the-proposed-tra
nsaction-to-competition-authoritires/11479. 
A further announcement will be made when appropriate.
This announcement is also available on AB Sanitas' website:
www.sanitasgroup.com. 

 A person authorised to provide additional information: Mr. Saulius Jurgelėnas,
Chief Executive Officer of AB Sanitas, phone number +370 686 67779. 


         Lawyer
         Dovilė Morkytė
         +370 615 15163